Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716129 | 0.87 | CYP11B1 (0.41) | ADORA2ACYP19A1CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL4713845 | 0.84 | BRD4 (0.46) | CREBBPALDH1A1 | |
| SCHEMBL4716315 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPT | |
| SCHEMBL4713858 | 0.82 | MAPT (0.46) | CYP11B1CYP11B2ALDH1A1MAPT | |
| SCHEMBL4711849 | 0.79 | TP53 (0.51) | MAPT | |
| SCHEMBL4761608 | 0.77 | MAPT (0.36) | L3MBTL1ALDH1A1MAPT | |
| SCHEMBL4715863 | 0.77 | CYP3A4 (0.46) | L3MBTL1CCR2ALDH1A1MAPT | |
| SCHEMBL4714110 | 0.76 | LMNA (0.44) | L3MBTL1CYP11B1CYP11B2ALDH1A1MAPT | |
| SCHEMBL5113137 | 0.75 | HTR6 (0.44) | ALDH1A1 | |
| SCHEMBL4715873 | 0.75 | TP53 (0.46) | CYP11B1CYP11B2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2006-06-08 | — | — | US | claimed |
| US-7456286-B2 | Bicyclic heteroaromatic compounds as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2008-11-25 | — | — | US | disclosed |
| EP-1549648-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2008-11-12 | — | — | EP | disclosed |
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| EP-1549648-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | Celltech R & D Limited (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031188-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | MAP2K2, MAP2K7, MAP2K3 | L3MBTL1 2135/4885ADORA2A 2236/4885CREBBP 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.